Since its inception, TVM Capital has raised more than €1.3 billion ($1.3 bn) in investment capital, and the firm is currently investing from its sixth generation of venture capital funds. To offer a higher degree of flexibility to investors, our fifth fund generation marked a split into two dedicated industry-specific fund entities for life sciences and technology investments. In all its funds, TVM Capital has a strong global base of Limited Partners, including investors from Europe, the United States, and Asia.
TVM Life Science Ventures VI (vintage 2005, €240.3 million ($298.9 m)) As with previous funds, TVM LSV VI maintains a strong emphasis on investments in the fields of drug discovery and development and is funding companies through all stages in the U.S. and Europe. The fund had its first IPO in June 2006 with the listing of BioXell in Switzerland and its second IPO with Newron, also in Switzerland.
TVM V Information Technology (vintage 2002, €128 million ($121.1 m)) TVM V IT was the largest German high tech venture capital fund raised in 2002. The fund’s investments have been focused in the areas of business software, semiconductors and components, wireless and telecommunications, media content and environmental technologies. The fund has primarily invested in early stage businesses that are now emerging as leaders in their fields such as the wireless infrastructure company Ubidyne, the new battery technology company Revolt and the web conferencing company Netviewer.
TVM V Life Science Ventures(vintage 2001, €336 million ($301.1 m)) TVM Capital’s first dedicated life sciences fund focused primarily on early stage investments throughout Europe and the United States. The sector focus remained unchanged from previous investments, with a strong emphasis on platform technologies that enhance drug discovery, integrated drug discovery, drug delivery and drug development companies. IPOs from this fund have included Addex, Acorda, Sirtris and Jerini. Strategic corporate buyers bought Jerini and Sirtris in 2008.
